[VIRTUAL] PRELIMINARY RESULTS OF THE FIRST PROSPECTIVE MULTI-INSTITUTIONAL TREATMENT STUDY IN CHILDREN WITH B-CELL NON-HODGKIN LYMPHOMA/LEUKEMIA (CCCG-BNHL-2015): A REPORT FROM THE CHINESE CHILDREN’S CANCER GROUP

[VIRTUAL] ACHIEVEMENT OF A MAXIMAL CARDIOPULMONARY EXERCISE TESTING IN CHILDHOOD CANCER SURVIVORS

[VIRTUAL] TREATMENT AND OUTCOME OF CHILDREN WITH WILMS TUMOUR AT MUHIMBILI NATIONAL HOSPITAL, TANZANIA

[VIRTUAL] SURVIVAL OF PEDIATRIC HODGKIN PATIENTS TREATED WITH DOXORUBICIN, BLEOMYCIN, VINCRISTINE, ETOPOSIDE, PREDNISONE AND CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN, BLEOMYCIN, VINCRISTINE, AND DACARBAZINE AT A SINGLE INSTITUTION

[VIRTUAL] FOXO1-FUSIONS (PAX3-FKHR & PAX7-FKHR) IN NON-METASTATIC CHILDHOOD RHABDOMYOSARCOMA (RMS): PREVALENCE, RISK-MIGRATION AND IMPACT ON OUTCOME.

[VIRTUAL] VALUE OF ZOLENDRONIC ACID MAINTENANCE THERAPY IN PATIENTS WITH STANDARD RISK LOCALIZED EWING SARCOMA. REPORT FROM THE INTERNATIONAL EWING 2008 TRIAL.

[VIRTUAL] INTERNATIONAL, MULTICENTER PHASE II TRIAL WITH HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY NAXITAMAB FOR TREATMENT OF REFRACTORY/RELAPSED HIGH-RISK NEUROBLASTOMA: EFFICACY AND SAFETY DATA

[VIRTUAL] LAROTRECTINIB DEMONSTRATES DURABLE EFFICACY AND SAFETY IN AN EXPANDED DATASET OF PEDIATRIC PATIENTS WITH TRK FUSION CANCER

[VIRTUAL] UPDATED ENTRECTINIB DATA FROM A PHASE 1/2 TRIAL IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

[VIRTUAL] SAFETY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF COBIMETINIB IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSED SOLID TUMOURS: IMATRIX-COBI, A PHASE I/II STUDY

[VIRTUAL] PHASE 1 STUDY OF TAZEMETOSTAT, AN ENHANCER OF ZESTE HOMOLOG-2 (EZH2) INHIBITOR, IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY INTEGRASE INTERACTOR 1 (INI1)-NEGATIVE TUMORS